Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.33 |
| ▸ | UNG | P13051 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1803456 | 0.84 | ALDH1A1 (0.38) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL29561757 | 0.84 | ALDH1A1 (0.38) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL27761248 | 0.82 | ALDH1A1 (0.36) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL4405513 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL4402546 | 0.80 | CYP2A6 (0.39) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL4408087 | 0.80 | CYP2A6 (0.39) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL7640569 | 0.80 | ALDH1A1 (0.39) | ALDH1A1MAPTTDP1TSHR | |
| SCHEMBL29521419 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL4402532 | 0.77 | ALDH1A1 (0.41) | ALDH1A1MEN1GAAMAPTHPGD | |
| SCHEMBL275981 | 0.74 | TUBB4A (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952493-B2 | Moisture-curing polyurethane composition containing oxazolidine | SIKA TECHNOLOGY AG (CH) | 2024-04-09 | — | — | US | disclosed |
| CN-113272299-B | Moisture-curable polyurethane compositions comprising oxazolidines | SIKA技术股份公司 | 2023-07-07 | — | — | CN | disclosed |
| EP-3898619-B1 | MOISTURE-CURABLE POLYURETHANE COMPOSITION CONTAINING OXAZOLIDINE | SIKA TECH AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| CN-110099951-B | Surface treated fillers for polyester films | OMYA国际股份公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20220025176-A1 | MOISTURE-CURING POLYURETHANE COMPOSITION CONTAINING OXAZOLIDINE | SIKA TECHNOLOGY AG (CH) | 2022-01-27 | — | — | US | disclosed |
| CN-113272299-A | Moisture-curing polyurethane composition comprising oxazolidine | SIKA技术股份公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-112105654-A | Curable resin mixture, curable resin composition, and cured product thereof | 日本化药株式会社 | 2020-12-18 | — | — | CN | disclosed |
| WO-2020031935-A1 | CURABLE RESIN MIXTURE, CURABLE RESIN COMPOSITION, AND CURED PRODUCT | 日本化薬株式会社 | 2020-02-13 | — | — | WO | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| EP-2188242-A2 | CYCLOHEXENE DERIVATIVES AND THEIR USE AS ODORANTS | Givaudan SA (CH) | 2010-05-26 | — | — | EP | disclosed |
| US-7700789-B2 | Heterogeneous catalyst and process for producing oxirane compound with the catalyst | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-04-20 | — | — | US | disclosed |
| EP-1632291-B1 | HETEROGENEOUS CATALYST AND PROCESS FOR PRODUCING OXIRANE COMPOUND WITH THE CATALYST | NISSAN CHEMICAL IND LTD (JP) | 2009-12-16 | — | — | EP | disclosed |
| EP-2106855-A1 | Heterogeneous catalyst and process for producing oxirane compound with the catalyst | Nissan Chemical Industries, Ltd. (JP) | 2009-10-07 | — | — | EP | disclosed |
| US-20090082583-A1 | Heterogeneous catalyst and process for producing oxirane compound with the catalyst | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| WO-2009021342-A2 | CYCLOHEXENE DERIVATIVES AND THEIR USE AS ODORANTS | GIVAUDAN SA (CH) | 2009-02-19 | — | — | WO | disclosed |
| US-20070093667-A1 | Heterogeneous catalyst and process for producing oxirane compound with the catalyst | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-04-26 | — | — | US | disclosed |
| EP-1632291-A1 | HETEROGENEOUS CATALYST AND PROCESS FOR PRODUCING OXIRANE COMPOUND WITH THE CATALYST | Nissan Chemical Industries, Ltd. (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-20050282730-A1 | Thrombopoetin receptor activator and process for producing the same | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| EP-1552828-A1 | THROMBOPOETIN RECEPTOR ACTIVATOR AND PROCESS FOR PRODUCING THE SAME | Nissan Chemical Industries, Ltd. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093667-A1 | Heterogeneous catalyst and process for producing oxirane compound with the catalyst | OXGR1, OXER1, OGFOD1 | ALDH1A1 800/4885MEN1 3099/4885GAA 1623/4885 |
| US-20090082583-A1 | Heterogeneous catalyst and process for producing oxirane compound with the catalyst | OXGR1, OGFOD1, OGDH | ALDH1A1 614/4885MEN1 3345/4885GAA 1608/4885 |
| US-20050282730-A1 | Thrombopoetin receptor activator and process for producing the same | PDGFRA, PTAFR, TBXA2R | ALDH1A1 2034/4885MEN1 2530/4885GAA 4869/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | ALDH1A1 2424/4885MEN1 4108/4885GAA 3709/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | ALDH1A1 1723/4885MEN1 2413/4885GAA 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.